asthma
GSK suffers Breo late-stage trial blow
September 9, 2015Research and Development COPD, GSK, Revlar, asthma, breo, clinical trial, phase III
GSK has hit a setback in its plans to expand sales of its blockbuster asthma treatment Breo, after a major …
GSK and Theravance see FDA nod for asthma indication
March 20, 2015Sales and Marketing Advair, AstraZeneca, Dulera, FDA, Foradil, GSK, Merck, Symbicort, Theravance, asthma, breo, budesonide/formoterol fumarate dihydratem, ellipta, fluticasone propionate, formoterol fumarate, mometasone/formoterol
An FDA panel has recommended the approval of asthma treatment Breo Ellipta in adults – but voted against supporting its …
AstraZeneca loses US Pulmicort patent
February 16, 2015Sales and Marketing AstraZeneca, Budesonide Inhalation Suspension, asthma, pulmicourt, respiratory
British drugmaker AstraZeneca has been dealt a blow by the courts in the US, after a district judge ruled its …
Vectura and J&J shake on asthma/COPD deal
January 6, 2015Research and Development, Sales and Marketing COPD, J&J, JJ, Janssen, asthma, johnson, rezolsta, tybost, vectura
British firm Vectura has entered an agreement with Johnson & Johnson’s pharma unit Janssen to develop therapies for asthma and …
Europe must prepare for COPD ‘timebomb’
November 19, 2014Sales and Marketing COPD, Europe, European COPD Coalition, Spiriva, asthma, chronic obstructive pulmonary disease
Health services in Europe are not making sufficient effort to cope with the escalating burden of chronic obstructive pulmonary disease …
Laser testing could lead to improved asthma therapies
November 13, 2014Research and Development, Sales and Marketing Oxford, asthma, pmdis, pope, stfc
UK scientists have used a laser beam trap to examine how drug particles from asthma inhalers travel through the air …
Boehringer’s Striverdi gains FDA approval
August 1, 2014Sales and Marketing Advair, COPD, Pfizer, Spiriva, asthma, olodaterol
Boehringer Ingelheim’s new lung drug Striverdi has gained US approval for patients with chronic obstructive pulmonary disorder. Striverdi Respimat (olodaterol), …
CHMP breathes new life into GSK, Teva and Novartis
February 24, 2014Research and Development, Sales and Marketing CHMP, COPD, EMA, GSK, Gilead, Teva, asthma, onoro
The CHMP has given its backing to a number of new treatments for respiratory diseases, which include two from London-based …
GSK banks on bioelectronics with new fund
August 9, 2013Medical Communications, Research and Development, Sales and Marketing Bioelectronics, COPD, GSK, asthma, diabetes
GSK has established a $50 million venture capital fund to invest in the emerging field of bioelectronics. Described as one …
Positive news for Sanofi asthma drug
May 23, 2013Sales and Marketing Dupilumab, Regeneron, Sanofi, asthma
An asthma drug being developed by Sanofi and Regeneron Pharmaceuticals has performed well in a Phase IIa trial, reducing the …
GSK severe asthma drug progresses to Phase III
August 20, 2012Research and Development, Sales and Marketing Advair, GSK, Phase II, asthma, phase III
GlaxoSmithKline’s severe asthma drug mepolizumab has impressed in a mid-stage study, meaning it can now progress into Phase III testing. …
Mobile monitoring of asthma ‘no better’ than traditional methods
March 26, 2012Medical Communications BMJ, Mobile monitoring, apps, asthma, smartphone
Mobile phone monitoring of asthma is ‘more expensive and no better than paper monitoring’, says new research. Findings published in …
Underwhelming results for GSK’s Relovair
January 10, 2012Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma
GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …
First personalised asthma drug shows promise
August 4, 2011Roche, asthma, personalised medicine
Roche’s personalised asthma drug lebrikizumab has met its primary end point in a phase II trial. Lebrikizumab increased the level …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
